Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials TranscriptSeeking Alpha · 1 day ago
Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data InsufficientBenzinga · 1 day ago
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension TrialsGlobeNewsWire · 1 day ago
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE DataGlobeNewsWire · 2 days ago
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to BuyZacks Investment Research · 3 days ago
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your BehalfGlobe News Wire · Oct 15, 2026Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.87 | -$0.66 | Beat |
| May 7, 2026 | -$0.88 | -$0.99 | Miss |
| Mar 23, 2026 | -$0.83 | -$0.81 | Beat |
| Nov 13, 2025 | -$0.80 | -$0.75 | Beat |
| Aug 13, 2025 | -$0.60 | -$0.66 | Miss |
| May 14, 2025 | -$0.67 | -$0.71 | Miss |